Q-Metrx provides quality controlled services for electro-physiological data collection, quantitative analysis, data management, statistical analysis, and publication of findings.
Q-Metrx has experience with subjects ranging from
- Healthy Normal Volunteers
To people suffering from:
- Alzheimer’s Disease
- Essential Tremor
- Major Depressive Disorder
- Periodic Limb Movement Syndrome/Disorder (PLMS/D)
- Restless Legs Syndrome (RLS)
- Seizure Disorders
- Sleep Apnea
Q-Metrx has clinical trial experience with drugs/compounds and medical devices for the treatment of various conditions, diseases and disorders.
With the aid of the pharmaco-EEG, essential information can be obtained in early drug development regarding CNS penetration and efficacy of new substances as follows:
- Evidence for substance penetration (bioavailability) in the CNS on the basis of PD changes. In addition to the classic PK parameters (e.g., tmax, Cmax, AUC and t½), EEG/ERP parameters can be used to demonstrate time- and dose-effect correlations.
- Proof of CNS effects of a substance by comparison of quantitative EEG (qEEG/ERP) changes between pre- and post-dose measurements.
- Characterization of psychotropic properties of a substance by comparison with psychotropic class effects of marketed drugs. Classic psychotropic drugs show typical pharmaco-EEG profiles, thus allowing assignment of new substances in many cases.
- Determination of new substance’s therapeutic window. The dose at which a new substance can be statistically distinguished from placebo, and at which it displays a psychotropic effect in comparison with a reference preparation, is often a therapeutically effective dose.
- Proof of adverse CNS effects of non-psychotropic substances (e.g., sedation produced by anti-hypertensive drugs or anti-histamines, changed convulsion threshold due to antibiotics).
- Determination of the bioequivalence of two different galenic dosage forms by quantitative comparison of CNS changes.